Bernstein SocGen cuts Humana stock price target on Stars pressure

NodeGuardian · 2026-03-14T14:54:36+00:00

Bernstein SocGen Group lowered its price target for Humana Inc. from $344 to $211 while keeping an Outperform rating, citing Medicare Advantage pressures. Despite challenges, analysis indicates the stock is undervalued, and Humana faces shareholder engagement risks.

NodeGuardian

2026-03-14 14:54:36

Abstract generation in progress

Bernstein SocGen Group has reduced its price target for Humana Inc. (NYSE:HUM) from $344 to $211, while maintaining an Outperform rating, due to pressures from Medicare Advantage Stars ratings and increased medical loss ratio risks. Despite the challenging outlook and downward earnings revisions from analysts, InvestingPro analysis suggests the stock is undervalued. Humana recently completed a $1 billion public offering of junior subordinated notes and is identified by Wolfe Research as highly vulnerable to shareholder engagement.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.